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Abstract.  Mouse cerebellar cells in culture secrete tis- 
sue plasminogen activator (tPA)  into the culture 
medium.  Fibrin overlays have shown tPA to be as- 
sociated with granule  neurons in these cultures.  This 
cell associated tPA can be displaced by extensive 
washing of the cells or by a brief lowering of the pH 
(<4),  which leads to a  loss of fibrinolytic activity by 
the cells.  Incubation of these fibrinolytically inactive 
cells with exogenously added murine tPA leads to the 
restoration of the fibrinolytic activity, indicating  the 
presence of tPA binding sites on these granule  neu- 
rons.  Using  '25I-tPA, the binding to cerebellar granule 
neurons is rapid,  saturable,  specific, high affinity (Kd 
=  50 pM) and reversible. Both murine and human 
tPA compete with  t25I-tPA for binding,  while both mu- 
rine and human urokinase (uPA) as well as human 
thrombin and plasminogen  fail  to compete. Neither the 
catalytic site nor the carbohydrate moiety of tPA appear 
to be involved in the binding,  since both diisopropyl- 
fluorophospate-treated tPA and endoglycosidase-H- 
treated tPA compete with  ~2I-tPA for binding.  Further- 
more, epidermal growth factor does not compete well 
with tPA for binding even at a  10:1 molar excess, sug- 
gesting that the epidermal growth factor-like (EGF) 
domain of tPA may not be involved in the binding 
mechanism.  Autoradiography and antibody immu- 
nofluorescence show the specific tPA binding  is to 
granule  neurons in these cultures.  Thus,  granule  neu- 
rons possess tPA receptors on their surface,  where this 
protease binds retaining  its functional activity and may 
play a  role in cell and axon migration. 
C 
EREBELLAR development is characterized  by exten- 
sive axonal growth and migration  of its granule neu- 
rons. Although these axonal and cell movements have 
been proposed to occur by purely physical means and likened 
to "battering  rams" (7), more recent studies  have suggested 
the possibility that extracellular proteases may facilitate these 
movements (21-24, 29, 42) by locally digesting cell-cell and 
cell-matrix  adhesions.  Plasminogen  activators  (PAs)' are 
the best documented extraceilular  proteases involved in cell 
movement and tissue remodeling (12). Thus, it is not surpris- 
ing that PA activity is elevated in rodent brain at the time of 
active cell migration  (21, 38, 41) and that PA is actively se- 
creted into the culture medium by dissociated cerebellar cells 
(38).  The PA activity in these cultures has been localized to 
the granule  cells by a fibrin clot overlay (22).  Using an anti- 
body to tissue plasminogen activator (tPA), the interaction of 
this anti-tPA with live granule cells in culture indicated that 
tPA was associated with the surface of these cells (39). 
The present study demonstrates a tPA receptor on develop- 
ing granule cell neurons and characterizes  some properties 
of this binding. A preliminary report of these findings has ap- 
peared (Verrall,  S.,  and  N.  W.  Seeds.  1987. Z  Cell Biol. 
105:319a  [Abstr.]). 
1. Abbreviations used in this paper: BEM, basal Eagle's medium; PA, plas- 
minogen activator; tPA, tissue PA; uPA, urokinase. 
Materials and Methods 
Cell Culture 
Cerebella were removed from postnatal day eight mice and the finely diced 
tissue was dissociated enzymatically in 0.17% trypsin in saline I (0.138 M 
NaC1, 5.4 mM KC1, 1.1 mM Na2HPO4,  1.1 mM KH2PO4) containing 0.4% 
glucose, 0.01% CaCI2,  and 3  #g/ml  DNase  (United States Biochemical 
Corp., Cleveland, OH) and incubated at 37°C with constant rotation for 12 
rain. The dissociation medium was replaced by basal Eagles medium (BEM) 
containing 10% heated (for 30 rain at 56°C, which inactivates residual tPA) 
FCS, and the tissue was dispersed by gentle pipetting and passed through 
a nylon screen to collect single cells. Cells were collected by centrifugation 
and enriched for granule cells by adsorption of nonneuronal cells on glass 
beads during an hour incubation in BEM with 10% FCS. The nonattached 
neurons were aspirated from the medium surrounding the beads and col- 
lected by centrifugation. The cells were resuspended in BEM with  10% 
acid-treated (20)  FCS  and plated at  200,000  cells/cm  2 on poly-o-lysine 
coated rectangular plastic coverslips (Miles Scientific,  Naperville, IL). Rous 
sarcoma virus transformed vole (Microtus agretis) fibroblasts, clone IT (9), 
were grown in DME containing 5%  FCS. Conditioned medium was ob- 
tained by rinsing confluent cultures three times with saline I and incubating 
them in serum-free DME for 24 b. 
tPA and Other Proteases 
Murine tPA was isolated from serum-free conditioned medium from Rous 
sarcoma virus-transformed vole fibroblasts by adsorption on zinc chelate- 
agarose (Pharmacia Fine Chemicals, Piscataway, N J) as described by Rijken 
and Collen (36),  followed by immunoaflinity chromatography using Afli- 
gel-linked (Bio-Rad Laboratories, Cambridge, MA) anti-mouse-tPA IgG, 
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lated from antiserum on protein A-agarose (Pierce Chemical Co., Rockford, 
IL) (48). Briefly, pooled tPA fractions from the zinc cbelate-agarose column 
were applied to the immunoaffinity column (0.9 x  3.3 cm) equilibrated with 
0.2  M  ammonium bicarbonate (pH 7.5)  at a  flow rate of 0.5  ml/h. The 
column was extensively washed with the same buffer, the tPA eluted with 
0.1  M ammonium formate (pH 3). Fractions containing tPA were neutral- 
ized with 17% NH4OH, pooled and lypholized. A single protein species of 
approximate Mr 70,000  was observed in silver-stained (30) polyacrylamide 
gels under reducing (not shown) and nonreducing conditions (Fig. I a), sug- 
gesting the secretion of single-chain tPA molecules into the culture medium 
by the vole IT fibrohlasts. 
The tPA was radiolabeled with ~251-Na (Amersham International, Amer- 
sham, UK) using Iodo-Beads (Pierce Chemical Co.) for 15 min at 20"C. 
The free iodine was removed by passing the labeled protein over an exocellu- 
lose GF-S column (Pierce Chemical Co.), preequilibrated with 0.1 M Tris- 
HCI (pH 7.4) containing l  mg/ml BSA. Only a single radiolabeled species 
comigrating with murine tPA was seen (Fig.  l  b). DFP-IPA was prepared 
by treating the tPA with l0 mM diisopropyl-fluorophosphate  for 2 h at 20°C; 
the inactivation was > 97%. Carbohydrate depleted tPA was prepared as de- 
scribed by Little et al.  (25). 
Mouse urokinase (uPA) was prepared from mouse urine by affinity chro- 
matography on p-aminobenzamidine-agarose  (Pierce Chemical Co.) as de- 
scribed by Holmberg et al. 09), followed by passage over an anti-tPA-Affi- 
gel column to remove residual tPA. 
The amino-terminal 30 kD finger-domain fragment of human fibronectin 
(the generous gift of Dr. R  McGuire, University of Colorado Health Sci- 
ence Center) was prepared by mild trypsinization, and isolated following 
its exclusion from gelatin-Sepharose and its specific elution from heparin- 
agarose chromatography according to the procedure of Sekiguchi et al. (40). 
Human (melanoma) tPA, reference standard, was obtained from the Na- 
tional Institute for Biological Standards and Control, Hertfordshire, UK. 
Recombinant tPA (human) was from Genentech Inc. (San Francisco, CA). 
Human uPA was purchased from Calbiochem-Behring Corp. (San Diego, 
CA); receptor grade epidermal growth factor was from Collaborative Re- 
search,  Inc.  (Waltham,  MA);  and  human  plasminogen was  from  Kabi 
(Helena Laboratories, Beaumont, TX). Human alpha-thrombin was a gift 
from Dr. J. Fenton (Albany Medical College). Heparin (clinical grade; Up- 
john Corp., Kalamazoo, MI) was isolated by precipitation with 3 vol of  95 % 
ethanol, centrifuged, boiled for l0 rain, and then placed in ice at 0.25 mg/ml. 
Assays  for Plasminogen Activator 
tPA activity was quantified by a chromogenic assay of Gilboa et al.  (14), 
essentially as described by Hawkins and Seeds (17). tPA samples were in- 
cubated with plasminogen for 2 h followed by the addition of the chromo- 
genie plasmin substrate Kabi S-2251  for another 2 h. 
The  fibrin overlay  procedure of Todd  (45)  was  used as  modified by 
Krystosek and Seeds (22). The cultures were washed three times with saline 
1, coated with a drop of thrombin (50 U/ml), followed by a drop of crude 
fibrinogen (75% clottable; ICN Lisle, IL), and drained. The thin fibrin clot 
was  incubated  in  a  moist chamber  for 90  rain,  fixed and  stained with 
Coomassie brilliant blue and  mounted for microscopic observation and 
counting of the fibrinolytic zones. 
USl-tPA Binding Assay 
The binding experiments were performed on  5-6-d  cerebellar cultures 
grown on coverslips. Endogenous cell-bound PA was dissociated by rinsing 
the coverslips 3 times in saline l, 0.1 mM CaCI2,  1 mM MgCI2, and plac- 
ing the coverslips in 50 mM glycine-HCI (pH 3), 0.1 M NaCI for 5 min at 
20°C, then neutralizing rapidly with 0.5 M Hepes (pH 7.5),  and rinsing 5 
times in saline 1 (Ca, Mg). In some studies, the endogenous tPA was dis- 
placed by repetitive washings of  the cultures in serum-free  BEM over several 
hours. The rinsed coverslips were incubated for 30 min at 20°C with 1251- 
tPA in binding buffer (BEM containing 15 mM Hepes, 10 Kallikrein inhibi- 
tory units/ml aprotinin (Sigma Chemical Co., St. Louis, MO) and I mg/ml 
BSA), maintaining a final volume of 0.1 ml. The cells were rapidly washed 
5 times with saline 1 (Ca, Mg) and the cell-associated radioactivity was de- 
termined. Specific binding was defined as the difference  between cell-bound 
radioactivity in the absence and presence of  a 50-fold molar excess of  nonla- 
beled tPA. The binding data expressed in molar terms are based on the con- 
version of IU of tPA to its weight in grams as compared with the specific 
activity of the second international standard for tPA, 86/670.  Cerebellar cell 
number was determined on the basis of  DNA content (6) of  random cultures, 
using a value of 5 pico g  DNA/celI. 
Figure 1. Homogeneity ofmurine 
tPA.  Vole cell tPA  (2/zg)  eluted 
from the anti-tPA immunoattinity 
column shows only a single band 
after silver staining an SDS-PAGE 
(lane  a).  The  iodinated  murine 
tPA  used  in  the  binding  studies 
described  below  shows  only  a 
single radiolabeled band (25,000 
cpm)  when  resolved  on  SDS- 
PAGE. 
Competitive binding studies were performed by incubating the cell cul- 
tures with ~251-tPA in the presence of an excess of the competing protein. 
Percent  specific binding was  calculated as  described above  for  specific 
binding. 
Au toradiography 
~25I-tPA binding to cerebellar cells was carried out as described above in 
the presence or absence of an excess of nonlabeled tPA. The rinsed cover- 
slips were fixed with 1.0% glutaraldehyde in saline 1 (Ca, Mg), rinsed in 
water and coated with NTB-2 emulsion (Eastman Kodak Co,  Rochester, 
NY), and exposed at 4°C for several days before development and counter- 
staining. 
Antibody lmmunofluorescence 
After 4 d in culture, cerebellar cells were switched to 10% AT-FCS in BEM 
for 16 h and then rinsed five times with BEM and incubated for 2 h in serum- 
free BEM.  ~2sI-tPA  (human recombinant) was incubated with the cells for 
15 min at room temperature. Diluted antibodies: Cbl-l, a neuron specific 
rabbit antibody (37), or rabbit anti-fibronectin (Collaborative Research Inc.) 
were added to the reaction and incubation continued for another 20 min. 
The coverslips were rapidly rinsed and fixed for  10 min in 4%  pamfor- 
maldehyde, rinsed, after which some coverslips were treated with -20"C 
methanol for 5 min, then incubated for 20 min with rabbit anti-glial fibril- 
lary acidic protein (11), and rinsed. All coverslips were incubated for 20 min 
with fluorescein-conjugated goat anti-rabbit IgG as described previously 
(10),  then rinsed, air dried and mounted for autoradiography with NTB2 
emulsion as described above. After development and processing, the cover- 
slips were viewed with an epifluorescence microscope (Carl Zeiss, Inc., 
Thornwood, NY) using a 63 x  planapochromat objective. Photographs were 
taken of both fluorescent and bright field images (Tri-X  Pan film; Eastman 
Kodak Co.). 
Results 
Plasminogen activator secreted by mouse cerebellar cells in 
culture is primarily tPA (>90%) with a small amount ofuPA 
(<10%). PA activity in the culture medium is highest at day 
3 and declines, while zones of fibrinolytic activity increase 
4-fold from day 3 to a high at day 6 (50). This observation 
coupled with the finding that antibody to tPA binds to the sur- 
face of granule cell neurons (39), suggested that the fibrino- 
lytic zones may reflect cell bound tPA.  This possibility was 
explored by attempting to displace cell bound tPA by a brief 
lowering of the pH; a procedure used successfully for uPA 
bound to fibroblasts (2). Fig. 2 shows that the fibrinolytic ac- 
tivity of the cultures (a) is lost after a brief exposure to low 
pH (b). The low pH treatment does not inactivate the tPA, 
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and Methods. The cells were rinsed and incubated for 5 min at 20°C with 50 mM phosphate buffer (pH 7.4), 0.1 M NaC1 (a), or 50 mM 
glycine-HCl  (pH 3), 0.1 M NaCI (b and c). The cells were rinsed in saline 1 and overlaid with a fibrin clot (a and b), or incubated 30 
min with 250 mlU RSV-vole cell-derived tPA in 0.25 mi Hepes (15 mM) buffered BEM containing  1 mg/ml BSA, and then rinsed and 
overlaid with a fibrin clot (c).  Bar, 50 #m. 
but  releases tPA  into the  culture  medium where it can be 
identified by zymography (50).  Furthermore,  incubation of 
these low pH-treated cerebellar cells with exogenous murine 
tPA for 30 min followed by several rinses in BEM shows (c) 
the restoration of plasminogen-dependent fibrinolytic activ- 
ity by the culture; indicating cell binding sites for tPA where 
tPA  retains its proteolytic activity. 
A more direct assessment oftPA binding to cerebellar cells 
is shown in Fig. 3 where J25I-tPA  displays rapid and specific 
binding, being readily competed with a 50-fold molar excess 
of unlabeled murine tPA.  The Kob~ =  0.152  min  -j  for this 
binding to cerebellar neurons. The binding is saturable with 
increasing tPA concentration as seen in Fig. 4 A. Scatchard 
analysis of these data (Fig.  4  B)  shows  t:5I-tPA binding to 
cerebellar cells is of high affinity with a Kd of interaction on 
the order of 5  x  10  -~  M  and  ,~30,000  binding  sites/cell. 
The  t25I-tPA binding is reversible with >75%  of the specif- 
ically bound t25I-tPA released by 15 rain incubation in tPA- 
free medium. 
Autoradiography of the cell bound  ~25I-tPA shows that the 
specific binding is localized to small (6/zm) granule neurons 
that tend to cluster in these cultures, although radiolabeled 
singlets and doublets are seen (Fig. 5 a). In the presence of 
a 50-fold molar excess of unlabeled tPA, nonspecific binding 
of the radioligand is seen (Fig.  5 b) over the coverslip and 
the larger and more extended glial and epithelial cells, and 
is not concentrated over the granule neuron clusters as seen 
in Fig. 5 a. The identity of the radiolabeled small round cells 
as granul  e neurons was further substantiated by double label 
experiments,  where an antibody Cbl-1,  specific for mouse 
neurons (37), was included in the binding assay and shown 
to bind to those same cells that showed high amounts of ~25I- 
tPA binding (Fig. 6, a and b). Similar results were found with 
tetanus toxin binding (data not shown). Although the granule 
neurons often cluster on top of astrocytes, the glial fibrillary 
acidic protein reactive glia do not bind the  ~25I-tPA to their 
surface (Fig. 6,  c and d).  Furthermore,  the possibility that 
the tPA was binding not to the cells but to fibronectin in the 
matrix  was  ruled  out  by antibodies  to  fibronectin,  whose 
binding does not coincide with the binding of ~25I-tPA (Fig. 
6, e and f). Thus, tPA binding is a property of granule neu- 
rons in these cultures. 
The binding of ~25I-tPA to granule neurons is specific for 
tPA (Table I); neither mouse nor human uPA compete for this 
tPA binding site.  Furthermore,  two other serine proteases, 
thrombin and plasminogen that have been reported to bind 
to cell surfaces 06, 27), do not effectively compete with tPA 
binding.  As expected from the fibrinolytic results (Fig.  1), 
tPA binding to the granule cells does not involve the catalytic 
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Figure 3. Time course of ~25I-tPA  binding to cerebellar ceils.  Cerc- 
bellar cultures (3 x  l0  s cells) on plastic coverslips were incubated 
with  150 pM ~25I-tPA  at 20°C in the absence (o) or presence  (/x) 
of a 50-fold molar excess of nonlabeled tPA. Specific binding (e) 
was determined  as the  difference between  total and  nonspecific 
binding as described in Materials and Methods. The results are an 
average of duplicate measurements. 
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Figure 4.  Saturation of t25I-tPA binding to cerebeilar 
cells. Cerebellar cultures (3  x  105 cells) were incu- 
bated with increasing amounts of ~25I-tPA for 30 min 
at 20°C  in the absence (o) or presence (zx) of a 50- 
fold  molar  excess  of nonlabeled  tPA  (,4). Specific 
binding was determined as described in Materials and 
Methods,  and  the  data  are  an  average of duplicate 
points. The experiment was repeated twice with simi- 
lar results. These data are also shown in a Scatchard 
plot (B). 
site,  since DFP-tPA competes with  '2sI-tPA for binding.  Al- 
though tPA with a blocked catalytic site can bind, tPA which 
loses  activity  upon  standing,  by  repetitive  freeze-thaws  or 
heat denaturation does not compete for binding to these sites. 
About  7%  of tPbis  mass is carbohydrate;  however,  remov- 
al  of the  mannose-rich  oligosaccharides  with  Endo-H  has 
no effect on tP.a/s binding  activity.  Furthermore,  epidermal 
growth factor, a molecule that shares structural and sequence 
homology  with  tPA  (3)  shows  very  little  competition  for 
binding  even at a  10-fold  molar excess.  Heparin,  which  is 
known  to bind to tPA and enhance  its activity (1),  has also 
been implicated in the cell binding of several proteins (26); 
however, heparin has little apparent effect on tPA binding to 
granule neurons.  The amino-terminal fibronectin-like finger 
domain of tPA has been implicated in tPb2s interaction  with 
fibrin (3, 46).  Therefore, the finger domain of human fibro- 
nectin was tested for its ability to compete with human  '2sI- 
recombinant  tPA  (whose  binding  properties  are  similar  to 
that of murine tPA). A  100-fold molar excess of this fibronec- 
tin finger region showed <20% decrease in the specific bind- 
ing of tPA (data not shown). 
Unless bound ligand is displaced by lowering the pH, very 
Figure 5. Autoradiography of t2Sl-tPA binding to cerebeilar granule neurons. Cerebeilar cells were washed at pH 3 to displace endogenous 
tPA, and incubated 30 min with 1 IU of ~2sI-tPA  (a and b) and 50 IU unlabeled tPA (b). Small granule neurons at top and in center cluster 
(a) show specific binding of tPA,  not seen on granule cell clusters in (b), where only nonspecific binding remains.  Specific binding is 
seen only over granule neurons;  glia and nonneuronal  cells showed only nonspecific binding of ligand.  Bar,  15 #m. 
The Journal of Cell Biology, Volume 109, 1989  268 Figure 6.  Neuronal cell surface labeling and tzsI-tPA binding. Cell identity and t251-tPA binding were monitored simultaneously by im- 
munofluorescent antibody (a, c, and e) and bright field autoradiography (b, d, and f) of the same fields. Rabbit anti-Cbl-1 (a), a neuron- 
specific cell surface marker (37), was used to visualize cerebellar neurons in these cultures, and this antigen colocalized with ~25I-tPA 
binding (b). tPA binding (d) was not associated with astrocytes (c, glial fibrillary acidic protein). Very little fibronectin is seen in cerebellar 
cultures as visualized with rabbit anti-fibronectin (e) and fibronectin did not colocalize with the  Jz5I-tPA binding (f). Bar, 15 tim. 
little ~2q-tPA binds to 6-d cerebellar cell cultures; suggest- 
ing that the receptors are saturated under these conditions. 
However, endogenously bound tPA should be freely revers- 
ible and  subject to dilution of the free-tPA concentration. 
Repetitive media changes bring about a reduction in the free- 
tPA concentration, such that bound tPA is released into the 
medium and  ~2q-tPA binding to these cells increases (data 
not shown). Similarly, Fig. 7 shows the effect of diluting the 
free-tPA concentration on  release  of cell-bound tPA.  Re- 
leased tPA is seen asan increase in tPA in the medium as as- 
sessed by the amidolytic assay, while there is a parallel loss 
of cell-bound tPA activity as indicated by the decrease in the 
relative  number  of fibrinolytic zones  associated  with  the 
Table L  Specificity  of 12~I-tPA Binding to 
Cerebellar Neurons 
Nonlabeled protein  Amount  Molarity  Binding % 
None  0  0  100 
Murine tPA  32.5  IU  11.5  nM  0 
Human tPA  32.5  IU  l 1.5  0 
Murine urokinase  32.5  IU  11  106 
Human urokinase  32.5  IU  10  il0 
Human thrombin  36 ng  11.5  94 
Human plasminogen  110  ng  11.5  78 
Murine DFP-tPA  75  ng  11.5  5 
Murine denatured tPA  75  ng  11.5  100 
Deglycosylated tPA  32.5  IU  11.5  0 
Heparin  24  ng  11.5  93 
Epidermal  growth  factor  O. 15  ng  0.23  102 
Epidermal  growth  factor  1.5  ng  2.3  86 
Cerebellar  cells  were  stripped  of endogenous PA  by  mild  acid  treatment, 
washed, and incubated for 30 min at 20°C with murine ~2"~I-tPA  (0.65 IU  = 
1.5 ng= 0.23 nM) in the absence or presence of an excess of nonlabeled com- 
petitors, as indicated.  Percentage of (specific)  binding was calculated relative 
to inhibition by a 50-fold molar excess of active nonlabeled tPA. 
cells.  The dissociation rate constant  (k2) is 0.10 min  -~  for 
the reversibility of  endogenously bound tPA, when combined 
with the association constant k~  =  7  ×  108 M -t min  -~ cal- 
culated from K,,b~ (Fig.  3),  the Kj (70 pM) obtained from 
these kinetic data agrees well with the Kd obtained from the 
Scatchard plot (Fig. 4). 
Discussion 
These studies have demonstrated the specific binding of tPA 
to the surface of developing granule neurons. This binding 
is rapid, saturable, reversible, and of high affinity; further- 
more, tPA  interacts with the cell surface in such a  manner 
that tPA retains its full proteolytic activity. This localization 
of tPA to the cell surface provides an optimal site to facilitate 
cell movement. 
Since DFP-tPA competes for the tPA receptor, the catalytic 
site is not involved in this binding, contrary to other reports 
of high  affinity binding  to  endothelial cells  where tPA  is 
bound covalently via the active site, presumably to a  plas- 
minogen activator inhibitor (4, 5). The most likely portion 
of the tPA  molecule to be involved in  cell  binding  is  the 
amino terminal one-half. This proposal is supported by our 
observation  that  only  the  65,000-M~  form  of tPA  is  dis- 
placed from the cells by low pH,  although the 32,000-Mr 
catalytic carboxyl one-half of the tPA is seen in the culture 
medium (50). The amino-terminal portion of the tPA mole- 
cule contains several domains that are shared by other pro- 
teins and proteases (31). The finger domain characteristic of 
fibronectin (3), the growth factor domain that is similar to 
epidermal growth factor and  is also found in uPA  (3), the 
kringles (Nos.  1 and 2), similar to those in plasminogen and 
uPA (32, 35), are all candidates for this binding interaction; 
however,  the  failure of epidermal growth  factor,  uPA  and 
plasminogen  to  compete effectively for binding  make  the 
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Figure 7. Displacement of cell-bound tPA by dilution at neutral pH. 
After 5 d of culture, cerebeUar cells were switched to serum-free 
BEM overnight; then the medium was changed again, and the cul- 
tures were monitored simultaneously for zones of fibrinolytic activ- 
ity indicative of cell-bound tPA ( - <3-), and for tPA released into 
the medium as monitored by the amidolytic assay (-e-)  over the 
next 60 rain. 
growth factor domain and the kringle domains less likely 
candidates. Future studies with mutant tPA variants (13, 46) 
should clarify tP.~/s cell binding domain. 
Some of the properties described here for tPA binding to 
granule neurons are similar to those reported for uPA bind- 
ing by human monocytes and fibroblasts (2, 43, 47).  High 
affinity binding with a K~ =  4  x  10  -~° M and 60,000 bind- 
ing  sites/cell were found for single  chain 55,000  M,  uPA 
binding to monocytes (43, 47), as well as endogenously satu- 
rated  uPA  receptors  in  A431  epidermoid  cells  (44)  and 
fibroblasts (2). However, the tPA binding to granule neurons 
is specific for tPA, being blocked by antibody to mouse tPA 
(data not shown), and neither murine nor human uPA com- 
pete for binding to this granule cell tPA receptor. There have 
been very few previous reports of tPA binding, and these dis- 
cuss  binding  to  endothelial  cells  or  fibroblasts.  In  these 
reports, tPA binding was either irreversible (18) and often 
covalently bound via the catalytic site (4, 5), or of low affinity 
(Kd =  0.2/~M) with which uPA competes (4). Thus, the tPA 
receptor on  granule  neurons  appears  distinct  from these 
previous reports in its high affinity for tPA, reversibility and 
retention of enzymatic activity. 
Autoradiography of the cell bound ~25I-tPA shows that the 
specific binding in these granule cell-enriched cultures is 
limited to small ceils that have the nuclear morphology char- 
acteristic of granule neurons (Fig. 5), and bind tetanus toxin 
(22)  and  the  neuronal  specific antibody,  anti-Cbl-I  (37), 
while being negative for the astroglia marker, gliai fibrillary 
acidic protein (11) and epithelia marker, fibronectin (Fig. 6). 
Previous studies (22) have shown these small cells lack the 
oligodendroglia marker Og-1 (10).  Specific binding was not 
detected over those few gliai and nonneuronal cells in these 
cerebellar cultures. This finding agrees well with our previ- 
ous localization of fibrinolytic zones to only granule neurons 
in these primary cell cultures (22). However, it is readily ap- 
parent (Fig. 5) that not all granule neurons in these cultures 
bind  ~25I-tPA, similar to our observations with fibrin over- 
lays (22). Thus, the binding of tPA appears to be restricted 
to a subpopulation of granule neurons. This subpopulation 
may represent only those granule neurons actively involved 
in cell migration from the external to the internal granule cell 
layer of the cerebellum. This proposal is supported by obser- 
vations of granule neurons migrating on neural fascicles in 
culture that bind antibody to tPA  (39).  If only migrating 
granule cells have cell bound tPA, this adds an important new 
level of regulation to the PA-PA inhibitor (15, 21, 22, 28, 29, 
33, 34, 42) system; therefore, regulation oftPA receptor syn- 
thesis and membrane insertion may be the key steps. 
The presence of tPA receptors on granule neurons may be 
advantageous to the cell for several reasons.  Cell binding 
prevents diffusion of tPA away from the granule neuron. The 
tPA bound to the granule neuron receptor may be protected 
from inactivation by protease inhibitors present in the ex- 
tracellular environment, as has been demonstrated for mac- 
rophage uPA (8) and monocytes (44). Furthermore, the pos- 
sibility should not be overlooked that tPA may interact with 
its receptor in an autocrine system to elicit some second- 
messenger response within the cell. The tPA receptor pro- 
vides a mechanism whereby cells can "arm themselves" with 
functionally active protease. Furthermore, the receptor may 
permit both a temporal regulation as to when a cell may have 
this activity, and a  spatial regulation to provide for highly 
localized and concentrated areas of extracellular protease ac- 
tivity at sites of cell-cell and cell-matrix interaction. Thus, 
the process of cell and axonal migration may be regulated in 
part by the presence of a membrane tPA receptor and its oc- 
cupancy by tPA. 
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